The impact of lenvatinib on sarcopenia in patients with advanced unresectable hepatocellular carcinoma.

Humans Carcinoma, Hepatocellular / drug therapy Quinolines / therapeutic use Liver Neoplasms / drug therapy Phenylurea Compounds / therapeutic use Male Female Sarcopenia / drug therapy Aged Middle Aged Retrospective Studies Aged, 80 and over Protein Kinase Inhibitors / therapeutic use Antineoplastic Agents / therapeutic use Progression-Free Survival

Journal

Scientific reports

ISSN: 2045-2322

Titre abrégé: Sci Rep

Pays: England

ID NLM: 101563288

Informations de publication

Date de publication:
27 Sep 2024

Historique:

received: 03 04 2023

accepted: 03 07 2024

medline: 28 9 2024

pubmed: 28 9 2024

entrez: 27 9 2024

Statut: epublish

Résumé

Lenvatinib is a multiple receptor tyrosine kinase inhibitor (TKI) approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). TKI are suspected of exacerbating muscle loss in patients with cancer. In this study, we analyze the role of muscle loss in patients with advanced HCC treated with lenvatinib. This is a retrospective analysis of a real-life cohort of 25 patients with advanced HCC who were treated with lenvatinib from 2018 to March 2021 in Germany. Patients were stratified for loss of skeletal muscle area during the first three months of lenvatinib therapy. Overall survival (OS), progression-free survival (PFS) and toxicity were analyzed for all patients, especially regarding loss of muscle before and during the first three months of therapy with lenvatinib. Three months after beginning of therapy with lenvatinib, a significant reduction of muscle mass was observed in 60% of patients (p = 0.035). Despite increase of loss of skeletal muscle, patients benefitted from lenvatinib in our cohort of patients in terms of OS and PFS and did not experience increased toxicity. Furthermore, muscle loss was not a negative predictor of survival in the univariate analysis (p = 0.675). Patients with advanced hepatocellular carcinoma experience muscle loss with lenvatinib therapy. However, despite progressive muscle loss, patients benefit from a therapy with lenvatinib in terms of OS and PFS without increased toxicity. However, assessment and prophylaxis of skeletal muscle status should be recommended during a therapy with lenvatinib.

Identifiants

DOI: 10.1038/s41598-024-66766-8 PMID: 39333610

pubmed: 39333610

doi: 10.1038/s41598-024-66766-8

pii: 10.1038/s41598-024-66766-8

doi:

Substances chimiques

lenvatinib EE083865G2

Quinolines 0

Phenylurea Compounds 0

Protein Kinase Inhibitors 0

Antineoplastic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

22146

Informations de copyright

Références

Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424. https://doi.org/10.3322/caac.21492 (2018).

doi: 10.3322/caac.21492 pubmed: 30207593

Kanneganti, M. & Singal, A. G. Incidence of hepatocellular carcinoma in nonalcoholic fatty liver disease. Gastroenterology 162(6), 1772–1774. https://doi.org/10.1053/j.gastro.2022.01.037 (2022).

doi: 10.1053/j.gastro.2022.01.037 pubmed: 35120916

Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 7(1), 6. https://doi.org/10.1038/s41572-020-00240-3 (2021).

doi: 10.1038/s41572-020-00240-3 pubmed: 33479224

Vogel, A. & Martinelli, E. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann. Oncol. 32(6), 801–805. https://doi.org/10.1016/j.annonc.2021.02.014 (2021).

doi: 10.1016/j.annonc.2021.02.014 pubmed: 33716105

Galle, P. R. et al. EASL clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol. 69(1), 182–236. https://doi.org/10.1016/j.jhep.2018.03.019 (2018).

doi: 10.1016/j.jhep.2018.03.019

Abou-Alfa, G. K. et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J. Clin. Oncol. 40(4), 379. https://doi.org/10.1200/JCO.2022.40.4_suppl.379 (2022).

doi: 10.1200/JCO.2022.40.4_suppl.379

Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet 391(10126), 1163–1173. https://doi.org/10.1016/S0140-6736(18)30207-1 (2018).

doi: 10.1016/S0140-6736(18)30207-1 pubmed: 29433850

Ikeda, K. et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J. Gastroenterol. 52(4), 512–519. https://doi.org/10.1007/s00535-016-1263-4 (2017).

doi: 10.1007/s00535-016-1263-4 pubmed: 27704266

Rinninella, E. et al. Skeletal muscle loss during multikinase inhibitors therapy: Molecular pathways, clinical implications, and nutritional challenges. Nutrients 12(10), 3101. https://doi.org/10.3390/nu12103101 (2020).

doi: 10.3390/nu12103101 pubmed: 33053632 pmcid: 7601327

Nishikawa, H. et al. Japan society of hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol. Res. 46(10), 951–963. https://doi.org/10.1111/hepr.12774 (2016).

doi: 10.1111/hepr.12774 pubmed: 27481650

Praktiknjo, M. et al. Sarcopenia is associated with development of acute-on-chronic liver failure in decompensated liver cirrhosis receiving transjugular intrahepatic portosystemic shunt. Clin. Transl. Gastroenterol. 10(4), e00025. https://doi.org/10.14309/ctg.0000000000000025 (2019).

doi: 10.14309/ctg.0000000000000025 pubmed: 30939488 pmcid: 6602782

Praktiknjo, M. et al. Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis. Hepatology 67(3), 1014–1026. https://doi.org/10.1002/hep.29602 (2018).

doi: 10.1002/hep.29602 pubmed: 29059469

Prado, C. M. et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol. 9, 629–635. https://doi.org/10.1016/S1470-2045(08)70153-0 (2008).

doi: 10.1016/S1470-2045(08)70153-0 pubmed: 18539529

Shachar, S. S., Williams, G. R., Muss, H. B. & Nishijima, T. F. Prognostic value of sarcopenia in adults with solid tumors: A meta-analysis and systematic review. Eur. J. Cancer 57, 58–67. https://doi.org/10.1016/j.ejca.2015.12.030 (2016).

doi: 10.1016/j.ejca.2015.12.030 pubmed: 26882087

Perisetti, A. et al. Sarcopenia in hepatocellular carcinoma: Current knowledge and future directions. World J. Gastroenterol. 28(4), 432–448. https://doi.org/10.3748/wjg.v28.i4.432 (2022).

doi: 10.3748/wjg.v28.i4.432 pubmed: 35125828 pmcid: 8790553

Faron, A. et al. Combination of fat-free muscle index and total spontaneous portosystemic shunt area identifies high-risk cirrhosis patients. Front. Med. (Lausanne) 9, 831005. https://doi.org/10.3389/fmed.2022.831005 (2022).

doi: 10.3389/fmed.2022.831005 pubmed: 35492329

Tantai, X. et al. Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis. J. Hepatol. 76(3), 588–599. https://doi.org/10.1016/j.jhep.2021.11.006 (2022).

doi: 10.1016/j.jhep.2021.11.006 pubmed: 34785325

Meza-Junco, J. et al. Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J. Clin. Gastroenterol. 47(10), 861–870. https://doi.org/10.1097/MCG.0b013e318293a825 (2013).

doi: 10.1097/MCG.0b013e318293a825 pubmed: 23751844

Hsu, C. S. & Kao, J. H. Sarcopenia and chronic liver diseases. Expert Rev. Gastroenterol. Hepatol. 12(12), 1229–1244. https://doi.org/10.1080/17474124.2018.1534586 (2018).

doi: 10.1080/17474124.2018.1534586 pubmed: 30791794

Marasco, G. et al. Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments. J. Gastroenterol. 55(10), 927–943. https://doi.org/10.1007/s00535-020-01711-w (2020).

doi: 10.1007/s00535-020-01711-w pubmed: 32748172 pmcid: 7519899

Hiraoka, A. et al. Real-life practice experts for HCC (RELPEC) Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. J. Gastroenterol. Hepatol. 36(7), 1812–1819. https://doi.org/10.1111/jgh.15336 (2021).

doi: 10.1111/jgh.15336 pubmed: 33171524

Rinninella, E. et al. Minimal impact of lenvatinib (Lenvima®) on muscle mass in advanced hepatocellular carcinoma and implications for treatment duration. Two cases from the REFLECT study. Eur. Review for Med. Pharmacol. Sci. 23, 10132–10138. https://doi.org/10.26355/eurrev_201911_19583 (2019).

doi: 10.26355/eurrev_201911_19583

Endo, K. et al. Impact of grip strength in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Cancers (Basel) 12(8), 2146. https://doi.org/10.3390/cancers12082146 (2020).

doi: 10.3390/cancers12082146 pubmed: 32756366

Uojima, H. et al. Skeletal muscle mass influences tolerability and prognosis in hepatocellular carcinoma patients treated with lenvatinib. Liver Cancer 9(2), 193–206. https://doi.org/10.1159/000504604 (2020).

doi: 10.1159/000504604 pubmed: 32399433

Kotoh, Y. et al. Effect of handgrip strength on clinical outcomes of patients with hepatocellular carcinoma treated with lenvatinib. Appl. Sciences. 10(16), 5403. https://doi.org/10.3390/app10165403 (2020).

doi: 10.3390/app10165403

Dong, D. et al. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib. Medicine (Baltimore) 101(5), e28680. https://doi.org/10.1097/MD.0000000000028680 (2022).

doi: 10.1097/MD.0000000000028680 pubmed: 35119010

Surov, A., Thormann, M. & Hinnerichs, M. Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial. Hepatol. Commun. 7(6), e0165. https://doi.org/10.1097/HC9.0000000000000165 (2023).

doi: 10.1097/HC9.0000000000000165 pubmed: 37219875 pmcid: 10208699

Kitano, Y. & Yamashita, Y. I. Sarcopenia afects systemic and local immune system and impacts postoperative outcome in patients with extrahepatic cholangiocarcinoma. World J. Surg. 43(9), 2271–2280. https://doi.org/10.1007/s00268-019-05013-y (2019).

doi: 10.1007/s00268-019-05013-y pubmed: 31041559

Afzali, A. M. et al. Skeletal muscle cells actively shape (auto) immune responses. Autoimmun. Rev. 17(5), 518–529. https://doi.org/10.1016/j.autrev (2018).

doi: 10.1016/j.autrev pubmed: 29526638

Nelke, C. et al. Skeletal muscle as potential central link between sarcopenia and immune senescence. EBioMedicine 49, 381–388. https://doi.org/10.1016/j.ebiom.2019.10.034 (2019).

doi: 10.1016/j.ebiom.2019.10.034 pubmed: 31662290 pmcid: 6945275

Conlon, K. C. et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during frst-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 33, 74–82. https://doi.org/10.1200/JCO.2014.57.3329 (2015).

doi: 10.1200/JCO.2014.57.3329 pubmed: 25403209

March, C. et al. Prevalence and role of low skeletal muscle mass (LSMM) in hepatocellular carcinoma. A systematic review and meta-analysis. Clin. Nutr. ESPEN 49, 103–113. https://doi.org/10.1016/j.clnesp.2022.04.009 (2022).

doi: 10.1016/j.clnesp.2022.04.009 pubmed: 35623801

Guo, Y. et al. Association between sarcopenia and clinical outcomes in patients with hepatocellular carcinoma: an updated meta-analysis. Sci. Rep. 13(1), 934. https://doi.org/10.1038/s41598-022-27238-z (2023).

doi: 10.1038/s41598-022-27238-z pubmed: 36650190 pmcid: 9845331

Chang, K. V. et al. Association between loss of skeletal muscle mass and mortality and tumor recurrence in hepatocellular carcinoma: A systematic review and meta-analysis. Liver Cancer 7, 90–103. https://doi.org/10.1159/000484950 (2018).

doi: 10.1159/000484950 pubmed: 29662836

Meza-Junco, J. et al. Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J. Clin. Gastroenterol. 47, 861–870. https://doi.org/10.1097/MCG.0b013e318293a825 (2013).

doi: 10.1097/MCG.0b013e318293a825 pubmed: 23751844

Shimozato, N. et al. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in Japan. Anticancer Res. 42(1), 173–183. https://doi.org/10.21873/anticanres.15471 (2022).

doi: 10.21873/anticanres.15471 pubmed: 34969723

Tsuchiya, K. et al. The real-world data in Japanese patients with unresectable hepatocellular carcinoma treated with lenvatinib from a nationwide multicenter study. Cancers 13(11), 2608. https://doi.org/10.3390/cancers13112608 (2021).

doi: 10.3390/cancers13112608 pubmed: 34073396 pmcid: 8198233

Goh, M. J. et al. Efficacy and safety of lenvatinib therapy for unresectable hepatocellular carcinoma in a real-world practice in Korea. Liver Cancer 10(1), 52–62. https://doi.org/10.1159/000512239 (2021).

doi: 10.1159/000512239 pubmed: 33708639 pmcid: 7923940

Wang, D. X. et al. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China. World J. Gastroenterol. 26(30), 4465–4478. https://doi.org/10.3748/wjg.v26.i30.4465 (2020).

doi: 10.3748/wjg.v26.i30.4465 pubmed: 32874058 pmcid: 7438196

Nowak, S., Faron, A. & Luetkens, J. A. Fully automated segmentation of connective tissue compartments for CT-based body composition analysis: A deep learning approach. Invest. Radiol. 55(6), 357–366 (2020).

doi: 10.1097/RLI.0000000000000647 pubmed: 32369318

Luetkens, J. A. et al. Opportunistic computed tomography imaging for the assessment of fatty muscle fraction predicts outcome in patients undergoing transcatheter aortic valve replacement. Circulation 141, 234–236. https://doi.org/10.1161/CIRCULATIONAHA.119.042927 (2020).

doi: 10.1161/CIRCULATIONAHA.119.042927 pubmed: 31958246